A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Key Inclusion Criteria: * Over 18 years old * Histologically confirmed aggressive B-cell NHL, including: * MCL, with diagnosis confirmed by cyclin D1 overexpression or evidence of t (11;14) translocation * LBCL, including: * DLBCL NOS * Primary mediastinal LBCL * High-grade BCL * DLBCL arising from follicular lymphoma * Follicular lymphoma grade 3B * Richter's syndrome * Availability of archival tissue for immunohistology, or willing to undergo baseline biopsy if not available * R/R with no available therapy. Subject must have: * Received prior systemic therapy that has included an alkylating agent, anthracycline, and an anti-CD20 mAb * Received and progressed after autologous hematopoietic stem cell transplant (HSCT) or is ineligible for or has refused to receive HSCT * Received prior approved CD19 CAR T-cell therapy or is ineligible for or has refused CD19 CAR-T * Minimum washout period between previous systemic therapy and leukapheresis includes: * Chemotherapy: at least 14 days or 5 half-lives, whichever is shorter * Autologous HSCT: at least 3 months * CD19 CAR T-cell therapy: at least 6 months * ≥1 measurable lesion per Lugano criteria (Cheson, 2014) * Subject has Fluorodeoxyglucose (FDG)-avid disease. * Subject has an ECOG performance status of 0 or 1. * Subject has adequate organ function: * ALC ≥100/uL * ANC ≥1000/uL (≥500/uL if due to lymphoma; growth factors allowed) * Hgb ≥8 g/dL (transfusion allowed) * Platele…